Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca has reported results of the first large real-world evidence study of its kind evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving treatment with a newer class of diabetes medicines, SGLT-2 inhibitors (SGLT-2i).
Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has appointment Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017.
Oxford BioDynamics is one of six consortium partners to examine and address why immune-mediated inflammatory diseases (IMIDs) remit and relapse, with a particular focus on Rheumatoid Arthritis (RA).
Pharnext, a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, has enroled the first two patients to the international Phase 3 Extension Study PLEO-CMT-FU of PXT3003 at La Timone University Hospital (Marseille, France).
Stada’s Supervisory Board has postponed expert sessions which were planned as part of the structured bidding process.
Bone Therapeutics, the bone cell therapy company, has reported net loss of €13,02 million for 2016 which is slight decrease in loss comaring to last years €14,07 million net loss.
Shire said on Thursday that the European Commission (EC) has approved a label extension granting three new indications for CINRYZE® (C1 inhibitor [human]), broadening its use to children with Hereditary angiodema (HAE), a rare, genetic disorder that results in recurring attacks of edema (swelling). The body sites most commonly affected are mainly the extremities and abdomen.
Creso Pharma’s subsidiary HempIndustries s.r.o. (HI) has received regulatory approval in the Czech Republic to sell its new product line called diCBDIUM.
The approval by the Czech Ministry of Agriculture, means that HI can …
Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.
BASF, German based chemical company, has reported that it has raised prices of ethanolamines in Europe, effective immediately.